ERS 2025: Brinsupri's efficacy reinforced in subgroup analysis of bronchiectasis patients

At the ERS Conference 2025, Insmed's subgroup analysis from the Phase III ASPEN study reinforced the efficacy of Brinsupri (brensocatib) for treating non-cystic fibrosis bronchiectasis, impacting patient management strategies.

• Insmed presented findings on 30 September 2025 at the European Respiratory Society Conference in Amsterdam, emphasizing the efficacy of Brinsupri (brensocatib) in non-cystic fibrosis bronchiectasis patients.
• The Phase III ASPEN study (NCT04594369) demonstrated significant improvements in blood plasma markers and reduced adverse effects compared to placebo, enhancing treatment options for bronchiectasis.
• Subgroup analysis indicated that Brinsupri's oral administration is well-tolerated without increased hypertension risk, maintaining a favorable confidence interval for efficacy in diverse patient populations.